QL2111

Primary study objective: To study the pharmacokinetics of a single subcutaneous injection of the candidate drug QL2111 and the reference drug Emgality® in healthy subjects, and to evaluate the pharmacokinetic similarity of the two formulations for subcutaneous injection. Secondary study objective: To study the safety and immunogenicity of a single subcutaneous injection of the candidate drug QL2111 120 mg and the reference drug Emgality® 120 mg in healthy subjects.